Details of the Drug

General Information of Drug (ID: DM2F8XZ)

Drug Name

Salicyclic acid

Synonyms

Salicylic acid; salicylic acid; 2-Hydroxybenzoic acid; 69-72-7; o-hydroxybenzoic acid; 2-Carboxyphenol; o-Carboxyphenol; Salonil; Rutranex; Retarder W; Keralyt; Freezone; Duoplant; Saligel; Ionil; Psoriacid-S-stift; salicylate; Stri-Dex; Salicylic acid soap; Benzoic acid, 2-hydroxy-; Salicylic acid collodion; Verrugon; Phenol-2-carboxylic acid; Acidum salicylicum; Trans-Ver-Sal; Orthohydroxybenzoic acid; 2-Hydroxybenzenecarboxylic acid; Acido salicilico; Ionil-Plus; Salicylic acid, tech; Kyselina salicylova; Clear away wart remover; Duofil wart; Domerine; Duofilm; Occlusal; SAX; Salicylate; Sebucare; Sebulex; Acido salicilico [Italian]; Advanced pain relief callus removers; Advanced pain relief corn removers; Akurza Cream; Akurza Lotion; DHS Sal Shampoo; DuoPlant Gel; Duofil wart remover; Hydrisalic Gel; Ionil plus; Kyselina salicylova [Czech]; Mediplast pads; O Hydroxybenzoic Acid; Ortho Hydroxybenzoic Acid; Retarder SAX; Salex Cream; Salex Lotion; CMC_13852; K 537; ATA fraction 10, ammonium salt; Acid, Salicylic; Acido o-idrossibenzoico; Acido o-idrossibenzoico [Italian]; Kyselina 2-hydroxybenzoova; Kyselina 2-hydroxybenzoova [Czech]; O-Carboxyphenol; O-hydroxybenzoic acid; Ortho-Hydroxybenzoic Acid; P&S Shampoo; Phenol derivative, 7; Propa pH Peel-Off Acne Mask; SALICYLIC ACID (SEE ALSO ALPHA HYDROXY ACIDS); SALICYLIC ACID, ACS; Salicylic acid & Sulfur Soap; Salicylic acid (TN); Salicylic acid [USAN:JAN]; Acid, 2-Hydroxybenzoic; Acid, o-Hydroxybenzoic; Acid, ortho-Hydroxybenzoic; BENZOIC ACID,2-HYDROXY SALICYLIC ACID; Dr Scholl's callus removers; Dr Scholl's corn removers; Dr Scholl's wart remover kit; Salicylic acid (6CI,8CI); Salicylic acid (JP15/USP); Alpha/Beta Hydroxy Acids (Glycolic Acid, Salicylic Acid); Salicylic acid-ring-UL-14C; ALPHA/BETA HYDROXY ACIDS (SALICYLIC ACID) (SEE ALPHA/BETA HYDROXY ACIDS); Benzoic acid, 2-hydroxy-(9CI); E9A559BE-383B-4F83-BC02-3031D03D558A; 2 Hydroxybenzoic Acid; 2-hydroxy(1-14c)benzoic acid; SALICYLATE

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Approved	[1]
Acute coronary syndrome	BA41	Approved	[2]
Adenomatous colon polyp	N.A.	Approved	[2]
Allergic rhinitis	CA08.0	Approved	[2]
Back pain	ME84.Z	Approved	[2]
Common cold	CA00	Approved	[2]
Fever	MG26	Approved	[2]
Headache	8A80-8A84	Approved	[2]
Keratinization disease	N.A.	Approved	[2]
Migraine disorder	N.A.	Approved	[2]
Myocardial infarction	BA41-BA43	Approved	[3]
Osteoarthritis	FA00-FA05	Approved	[2]
Pain	MG30-MG3Z	Approved	[2]
Pityriasis simplex	N.A.	Approved	[2]
Seborrhoeic dermatitis	EA81	Approved	[4]
Tinea corporis	1F28.Y	Approved	[2]
Colon cancer	2B90.Z	Investigative	[5]
Rheumatoid arthritis	FA20	Investigative	[6]
Synovitis	N.A.	Investigative	[2]
Tinea pedis	1F28.2	Investigative	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antiinflammatory Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

138.12

Logarithm of the Partition Coefficient (xlogp)

2.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [7]
Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [8]
Elimination: About 10% of drug is excreted unchanged in the urine [9]
Metabolism: The drug is not metabolised [9]
Vd: The volume of distribution (Vd) of drug is 0.17 L/kg [9]
Water Solubility: The ability of drug to dissolve in water is measured as 2.51 mg/mL [7]

Chemical Identifiers

Formula: C7H6O3
IUPAC Name: 2-hydroxybenzoic acid
Canonical SMILES: C1=CC=C(C(=C1)C(=O)O)O
InChI: InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)
InChIKey: YGSDEFSMJLZEOE-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 338
ChEBI ID: CHEBI:16914
CAS Number: 69-72-7
DrugBank ID: DB00936
TTD ID: D07HBX
VARIDT ID: DR00556
INTEDE ID: DR1458

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carbonic anhydrase (CA)	TTUNARX	NOUNIPROTAC	Inhibitor	[10]
Carbonic anhydrase I (CA-I)	TTHQPL7	CAH1_HUMAN	Inhibitor	[11]
Carbonic anhydrase II (CA-II)	TTANPDJ	CAH2_HUMAN	Inhibitor	[11]
Carbonic anhydrase IV (CA-IV)	TTZHA0O	CAH4_HUMAN	Inhibitor	[11]
Carbonic anhydrase VI (CA-VI)	TTCFSPE	CAH6_HUMAN	Inhibitor	[11]
Carbonic anhydrase XII (CA-XII)	TTSYM0R	CAH12_HUMAN	Inhibitor	[11]
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[12]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Sodium-coupled monocarboxylate transporter 2 (SLC5A12)	DTM301H	SC5AC_HUMAN	Substrate	[13]
Probable small intestine urate exporter (SLC17A4)	DTHE530	S17A4_HUMAN	Substrate	[14]
Monocarboxylate transporter 2 (SLC16A7)	DTLT3UG	MOT2_HUMAN	Substrate	[15]
Monocarboxylate transporter 1 (SLC16A1)	DT342ZG	MOT1_HUMAN	Substrate	[16]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)_{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[17]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Gene/Protein Processing	[18]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Gene/Protein Processing	[19]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Gene/Protein Processing	[18]
Caspase-1 (CASP1)	OTZ3YQFU	CASP1_HUMAN	Post-Translational Modifications	[20]
Cytochrome P450 4A11 (CYP4A11)	OTPU5J0S	CP4AB_HUMAN	Gene/Protein Processing	[21]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Gene/Protein Processing	[20]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Gene/Protein Processing	[20]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Gene/Protein Processing	[22]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Gene/Protein Processing	[23]
Metallothionein-1A (MT1A)	OTKBH52X	MT1A_HUMAN	Gene/Protein Processing	[19]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Salicyclic acid (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Salicyclic acid caused by Sodium bicarbonate mediated altered urine pH.	Acidosis [5C73]	[24]
Tromethamine	DMOBLGK	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Salicyclic acid caused by Tromethamine mediated altered urine pH.	Acidosis [5C73]	[24]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Salicyclic acid and Glibenclamide.	Acute diabete complication [5A2Y]	[25]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Salicyclic acid and Insulin-glulisine.	Acute diabete complication [5A2Y]	[26]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Salicyclic acid and Insulin-aspart.	Acute diabete complication [5A2Y]	[26]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Salicyclic acid and Glipizide.	Acute diabete complication [5A2Y]	[25]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Salicyclic acid and Budesonide.	Asthma [CA23]	[27]
Ofloxacin	DM0VQN3	Moderate	Additive CNS stimulant effects by the combination of Salicyclic acid and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[28]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Salicyclic acid and Kanamycin.	Bacterial infection [1A00-1C4Z]	[29]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Salicyclic acid and Streptomycin.	Bacterial infection [1A00-1C4Z]	[29]
Gemifloxacin	DMHT34O	Moderate	Additive CNS stimulant effects by the combination of Salicyclic acid and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS stimulant effects by the combination of Salicyclic acid and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[30]
ABT-492	DMJFD2I	Moderate	Additive CNS stimulant effects by the combination of Salicyclic acid and ABT-492.	Bacterial infection [1A00-1C4Z]	[28]
Rabeprazole	DMMZXIW	Minor	Decreased absorption of Salicyclic acid due to altered gastric pH caused by Rabeprazole.	Bacterial infection [1A00-1C4Z]	[31]
Levofloxacin	DMS60RB	Moderate	Additive CNS stimulant effects by the combination of Salicyclic acid and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[28]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of nephrotoxicity by the combination of Salicyclic acid and Etidronic acid.	Bone paget disease [FB85]	[32]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Salicyclic acid and Drospirenone.	Contraceptive management [QA21]	[33]
Ardeparin	DMYRX8B	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Ardeparin.	Coronary thrombosis [BA43]	[34]
Rivaroxaban	DMQMBZ1	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Rivaroxaban.	Deep vein thrombosis [BD71]	[34]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Vilazodone.	Depression [6A70-6A7Z]	[35]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Milnacipran.	Depression [6A70-6A7Z]	[35]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Escitalopram.	Depression [6A70-6A7Z]	[35]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Desvenlafaxine.	Depression [6A70-6A7Z]	[35]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Clomipramine.	Depression [6A70-6A7Z]	[35]
Dexlansoprazole	DM1DBV5	Minor	Decreased absorption of Salicyclic acid due to altered gastric pH caused by Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[31]
Brinzolamide	DMBAPFG	Major	Increased plasma concentration of Salicyclic acid and Brinzolamide due to competitive binding of plasma proteins.	Glaucoma [9C61]	[36]
Dichlorphenamide	DMH7IDQ	Major	Increased risk of metabolic acidosis by the combination of Salicyclic acid and Dichlorphenamide.	Glaucoma [9C61]	[36]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Salicyclic acid and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[37]
Sodium acetate anhydrous	DMH21E0	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Salicyclic acid caused by Sodium acetate anhydrous mediated altered urine pH.	Hypo-osmolality/hyponatraemia [5C72]	[24]
Probenecid	DMMFWOJ	Moderate	Antagonize the effect of Salicyclic acid when combined with Probenecid.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[38]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Salicyclic acid and Exjade.	Mineral absorption/transport disorder [5C64]	[39]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Salicyclic acid and Deflazacort.	Muscular dystrophy [8C70]	[27]
Prasugrel	DM7MT6E	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Prasugrel.	Myocardial infarction [BA41-BA43]	[40]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Sibutramine.	Obesity [5B80-5B81]	[35]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Epoprostenol.	Pulmonary hypertension [BB01]	[41]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Iloprost.	Pulmonary hypertension [BB01]	[41]
Gatifloxacin	DMSL679	Moderate	Additive CNS stimulant effects by the combination of Salicyclic acid and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[28]
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Salicyclic acid and Dexamethasone.	Rheumatoid arthritis [FA20]	[27]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Salicyclic acid and Leflunomide.	Rheumatoid arthritis [FA20]	[37]
Methylprednisolone	DM4BDON	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Salicyclic acid and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[27]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Salicyclic acid and Pitolisant.	Somnolence [MG42]	[38]
Apixaban	DM89JLN	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Apixaban.	Thrombosis [DB61-GB90]	[34]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Brilinta.	Thrombosis [DB61-GB90]	[38]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Salicyclic acid and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[25]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Salicyclic acid and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[26]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Salicyclic acid and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[26]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Salicyclic acid and Plazomicin.	Urinary tract infection [GC08]	[29]
Betrixaban	DM2C4RF	Moderate	Increased risk of bleeding by the combination of Salicyclic acid and Betrixaban.	Venous thromboembolism [BD72]	[34]
-----------


⏷ Show the Full List of 48 DDI Information of This Drug

References

1	The influence of various factors on the human resident skin flora. Semin Dermatol. 1990 Dec;9(4):305-8.
2	A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
3	Fully biodegradable coronary stents : progress to date. Am J Cardiovasc Drugs. 2008;8(5):305-14.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4306).
5	Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998 Nov 19;41(24):4800-18.
6	Protein binding of tolmetin. Clin Pharmacol Ther. 1978 Dec;24(6):694-705.
7	BDDCS applied to over 900 drugs
8	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
9	FDA Approved Drug Products: HELIDAC Therapy (bismuth subsalicylate, metronidazole, and tetracycline)
10	Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
11	Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
12	The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
13	Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008;10(1):193-9.
14	A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
15	Clinical and Functional Relevance of the Monocarboxylate Transporter Family in Disease Pathophysiology and Drug Therapy. Clin Transl Sci. 2018 Jul;11(4):352-364.
16	H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
17	Aromatic hydroxylation of salicylic acid and aspirin by human cytochromes P450. Eur J Pharm Sci. 2015 Jun 20;73:49-56.
18	Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
19	A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
20	Some non-sensitizers upregulate CD54 expression by activation of the NLRP3 inflammasome in THP-1 cells. J Toxicol Sci. 2019;44(3):213-224. doi: 10.2131/jts.44.213.
21	Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.
22	Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood. 2001 Mar 15;97(6):1742-9. doi: 10.1182/blood.v97.6.1742.
23	CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
24	Berg KJ "Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency." Eur J Clin Pharmacol 11 (1977): 111-6. [PMID: 837963]
25	Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
26	Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
27	Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34. [PMID: 18956992]
28	Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
29	Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S "Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium." Clin Sci 91 (1996): 187-91. [PMID: 8795442]
30	Product Information. Avelox (moxifloxacin) Bayer, West Haven, CT.
31	Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325?mg + immediate-release omeprazole 40?mg) or enteric-coated aspirin 325?mg + enteric-coated omeprazole 40?mg - a randomised, phase 1, crossover study.?Aliment Pharmacol Ther. 2013;38(1):62-71. [PMID: 23692061]
32	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
33	Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70. [PMID: 2865667]
34	Fausa O "Salicylate-induced hypoprothrombinemia: a report of four cases." Acta Med Scand 188 (1970): 403-8. [PMID: 5490567]
35	Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
36	Cowan RA, Hartnell GG, Lowdell CP, Baird IM, Leak AM "Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function." Br Med J (Clin Res Ed) 289 (1984): 347-8. [PMID: 6432091]
37	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
38	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
39	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
40	Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
41	Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.